Time Stamps
- 02:06 PEARL 1: Rethinking âprovokedâ and âunprovokedâ venous clots
- 09:11 PEARL 2: Virchowâs Triad 201
- 17:01 PEARL 3: Inherited thrombophilia testing, part 1: the three protein deficienciesÂ
- 28:49 PEARL 4: Inherited thrombophilia testing, part 2: the two prothrombotic mutations
- 38:38 PEARL 5: Rewind and applications
Sponsor: Freed is an AI scribe that listens and writes your note in < 30 seconds. Freed learns your style over time and is HIPAA compliant!Â
Show Notes
PEARL 1: Rethinking âprovokedâ and âunprovokedâ venous clots
- The traditional teaching is that there are two major buckets for clots: âprovokedâ and âunprovokedâ.Â
- Provoked clots are clearly associated with a risk factor, eg. a patient who has a knee arthroplasty who then develops a calf DVT.Â
- Unprovoked clots are not clearly associated with a risk factor.Â
- The main question surrounding anticoagulation after DVT/PE is often âhow long do we keep anticoagulating?âÂ
- The provoked/unprovoked dichotomy is classically used to drive duration. Unprovoked clots have far higher recurrence rates than provoked clots [citation], with stark differences depending on the provoking factor.
- Provoked clots are treated for 3-6 months of short-term therapeutic AC.Â
- No difference has been found between 3 or 6 months. [citation]
- Unprovoked clots are treated long-term, typically indefinitely. The rationale is that unprovoked clots have some occult risk factor that persists with time.Â
- What is challenging is that some provoked clots can also have high risks of recurrence, if that provoking factor sticks around long-term.Â
- A long-term provoking factor would imply a persistent risk of future clot, which doesnât disappear after 3-6mo. Â
- When thinking about provoked clots, always think about âreversibilityâ of the provoking factor, since thatâs the driver of management.
- Our suggested âbucketsâ for thinking about AC duration:
- (1) Provoked-reversible clots: the classic short-term risk factors (surgical, trauma, air travel). Treat for the short-term, 3-6mo.Â
- (2) Provoked-irreversible clots: more nuanced risk factors which may persist (obesity, inflammatory disorders, cancer). Consider treating long-term, for as long as that risk factor sticks around.Â
- (3) Unprovoked clots: Treat indefinitely.
PEARL 2: Virchowâs Triad 201
- The elements of Virchowâs triad are:
- (1) Stasis: Slow or turbulent flow in a vessel, with sluggish flow promoting clot formation
- (2) Endothelial injury: disruption or injury to the vessel lining, exposing prothrombotic factors
- (3) Hypercoagulable state: Overactivation of the coagulation cascade, resulting in more platelet activation and fibrin clot formation
- Use Virchowâs triad to broaden your differential for potential risk factors for clot. Donât be too hasty to call a clot âunprovokedâ!Â
- Instead, carefully consider all potential contributors â and which ones are âreversibleâ and âirreversibleâ in your patient.Â
- Some underappreciated risk factors, by Virchowâs:
- Stasis:Â
- Immobility: post-stroke, air travel (but only if >5-6 hours, and this is a relatively weak risk factor)
- Sluggish flow: HFrEF
- Vascular obstruction: Tumor, pregnancy, anatomic abnormalities (eg May-Thurner syndrome)
- Hyperviscosity: polycythemia, leukemia, Waldenstromâs
- Endothelial injury:Â
- Spontaneous: bacteremia, skin and soft tissue infections, scarring from prior clot
- Iatrogenic: Indwelling catheters/lines, radiation therapy
- Hypercoagulable state:
- Primary hematologic causes: inherited thrombophilias, APLAS
- Secondary:Â
- Increase in prothrombotic factors: pregnancy, OCP use, or other high-estrogen state
- Loss of natural anticoagulants: cirrhosis, nephrotic syndrome
- There are some other hematologic conditions in this bucket: paroxysmal nocturnal hemoglobinuria (PNH), myeloproliferative neoplasms (MPNs), and certainly leukemias/lymphomas
- Stasis:Â
- Remember the strength and reversibility of all these risk factors can be a gray area. Donât hesitate to talk to a hematologist to sort things out.
PEARL 3: Inherited thrombophilia testing, part 1: the three protein deficienciesÂ
- There are two types of primary thrombophilias (aka hypercoagulable disorders):
- Inherited thrombophilias: what we usually refer to when weâre talking about testing for hypercoagulable states when someone has an unprovoked clot
- Acquired thrombophilias: The big do-not-miss in this category is APLAS, the subject of a future pearl. We are talking about inherited thrombophilias only for the next 2 pearls.
- The common âinherited thrombophiliaâ testing includes 5 disorders:
- Inherited protein deficiencies: Antithrombin III deficiency, Protein C deficiency, Protein S deficiency â these three are the focus of Pearl 3.Â
- Inherited prothrombotic mutations: Factor V Leiden, prothrombin G20210A â these two are the focus of Pearl 4.
- Antithrombin III (ATIII) deficiency:Â
- ATIII is one of our natural anticoagulants. It works to reduce the activity of the clotting cascade.Â
- To help you remember: heparin works through ATIII, by increasing its activity.Â
- ATIII deficiency is one item on your differential for heparin resistance â heparin resistance itself is a whole topic in itself for another day.Â
- Pitfalls with ATIII testing
- Things that can falsely imitate an inherited ATIII deficiency: anticoagulation with heparins or warfarin, large clot burden, high-estrogen state, nephrotic syndrome, or acute inflammation
- Things that can obscure a real inherited ATIII deficiency: testing while on a DOAC
- Protein C and Protein S deficiencies:
- These two are lumped together because they carry similar pathophysiology
- They prevent clots by inhibiting factors V and VIII in the coagulation cascade.Â
- Their synthesis is vitamin K-dependent.Â
- Pathophysiology connection: warfarin is a vitamin K antagonist, which temporarily creates a protein C- and S-deficiency in the first few days of initiation.Â
- This temporary deficiency of proteins C/S is the reason why warfarin temporarily creates a prothrombotic state when first started â it is one reason why a âbridgeâ is needed.Â
- Warfarin skin necrosis is also caused by the longer-term deficiency of proteins C/S associated with chronic warfarin use, which results in formation of microthrombi in the skin.
-
-
-
- Â
-
-
-
- Â Pitfalls with Protein C/S testing
- Things that can falsely imitate inherited protein C or S deficiencies: anticoagulation with warfarin or DOAC, large clot burden, high-estrogen state, nephrotic syndrome, acute inflammation, cirrhosis, or another vitamin K-deficient state
- These two are lumped together because they carry similar pathophysiology
- Protein testing is VERY tricky to interpret with all the caveats above. If tests have already been sent, your differential for an apparent âdeficiencyâ of ATIII/protein C/protein S is as follows:
- (1) A true, inherited deficiency
- (2) A secondary, temporarily-deficient state: related to clot burden, high-estrogen, inflammation, or underlying disease (nephrotic syndrome, cirrhosis)
- (3) A fake-deficiency: due to testing while on anticoagulation, since the anticoagulant can cause artifact in the test tube.
- With all the difficulties in interpretation, we recommend avoiding testing in the acute setting. Remember that with this testing, a âlowâ result can be a label that follows your patient for life. Â
- Lots of gray areas here â if youâre wondering whether testing might be beneficial, ask a hematologist for help!
PEARL 4: Inherited thrombophilia testing, part 2: the two prothrombotic mutations
- These tests look for germline genetic mutations, so theyâre not affected by your patientâs current health status, clot burden, or anticoagulation.
- However, they are subject to the general pitfalls of hypercoagulability testing:
- Factor V Leiden heterozygosity is quite common, but it has variable penetrance.Â
- Remember the majority of patients with FVL heterozygosity do not develop clots.Â
- Even FVL homozygosity does not mean your patient is guaranteed to clot.Â
- Finding your patient is FVL heterozygous does not mean itâs the reason they had their clot â it may very well be a bystander.Â
- There are many other common and underappreciated risk factors, such as obesity and age itself.Â
- Age >60 is itself considered a risk factor (though an irreversible one). A first clot at age 60 or greater would not be a reason to pursue hypercoag testing.Â
- How clots manifest in the patient and their family is just as important (if not more so) than the results of testing.Â
- A patient with little to no personal/family history of clot with positive testing, renders you less likely to believe that their mutation would be the cause of a hypothetical new clot â especially if they are older.
- Conversely, for a patient with a really strong family history and negative testing, that negative testing is not necessarily reassuring â they are all having clots for a reason.Â
- The results of testing do not change your choice of anticoagulant â all available anticoagulants are effective in any of these inherited thrombophilias.Â
- Testing can rarely impact the duration of therapy, but even among hematologists there are some significant differences in opinion.Â
- Factor V Leiden heterozygosity is quite common, but it has variable penetrance.Â
- When might you consider testing, knowing all these caveats?
- (1) In a young patient with an unexplained clot and a strong family history in family members <60
- (2) In a patient with a clot and some question of inherited disorder, with a child planning pregnancy, OCP use, or other high-estrogen state â testing might help guide their childâs care.Â
- (3) If you and your patient both feel they would benefit from testing to help them understand the nature of their condition. Just be prepared for how you might counsel them in the event their testing is positive (or negative).Â
- Donât hesitate to ask a hematologist if youâre thinking about testing for any of the above reasons! This is a challenging space with a lot of nuance.
PEARL 5: Rewind and applications
- Case 1: a 48 year old male with an ankle sprain followed by 2 days of immobility, found 1 week later with a DVT and subsegmental PE. Family history of unprovoked PE in his mother at age 50, and his sister with a provoked clot in the postpartum setting. Heâs admitted, already on a heparin drip.Â
- Type of clot: provoked-reversible
- His family history is moderately concerning, with an unprovoked clot in a relative under 60
- Tests you can send now: Factor V Leiden, prothrombin G20210A.Â
- You should not send the protein-deficiency tests (ATIII, protein C, protein S) while on anticoagulation.
- Management: start anticoagulation (to be continued for minimum 3 months) until he can see Hematology as an outpatient, to consider further inherited thrombophilia testing. Make sure he sees his PCP for age-appropriate cancer screenings.Â
- A reminder when you think about testing: think about whether you should send APLAS testing. In this case, with a reasonable provoking factor, a family history, and a lower-morbidity venous clot, weâd defer testing for APLAS.
- Case 2: A 40 year old female with DVT/PE after an ankle sprain, with a DVT in a 70 year old aunt. She has completed 3 months of DOAC. She has a 16 year old daughter whoâs considering an OCP.Â
- Type of clot: provoked-reversible
- Her family history is not very compelling: a first clot in a family member aged >60 is not a red-flag for an inherited disorder.Â
- It might be reasonable to test to inform her daughterâs choice of OCP.Â
- Tests you can send now: any of them, since sheâs off AC! Factor V Leiden, prothrombin G20210A, ATIII, protein C, protein S.Â
- Management: Consider testing for all of the above to inform her daughterâs care. In the meantime, 3 months of AC is probably sufficient, since our overall suspicion for an inherited disorder is low. If a test were to be positive, refer to Hematology for more risk-benefit discussion.
Transcript
Dr. Rebecca Karp-Leaf: And I think that one of the reasons I love hematology, but also found it, sort of, anxiety provoking in the beginning, is you really have to get comfortable with this uncertainty.
Dr. Marty Fried: Welcome to Core IM 5 Pearls Podcast, bringing you high-yield, evidence based pearls! Thatâs Dr. Rebecca Karp-Leaf, a hematologist at Massachusetts General Hospital and one of our experts that weâll hear throughout this episode. Iâm Dr. Marty Fried, general internist and addiction doc at THE Ohio State Wexner Medical Center. Great to be back and SUPER excited to be working with the wonderful Dr. Sam Kumarasena.
Dr. Samantha Kumarasena: Hi everyone, Iâm Sam, a Heme-Onc and Palliative fellow at the Beth Israel Deaconess Medical Center in Boston, MA. In todayâs episode, weâre zooming into what has become one of my favorite hematology topics — clotting and hypercoagulability.Â
Dr. Marty Fried: Pearl 1: Reframing provoked and unprovoked venous thromboembolism
Dr. Samantha Kumarasena: What are some major precipitants that lead us to call a clot provoked⊠versus unprovoked?Â
Dr. Marty Fried: Pearl 2: Virchowâs Triad 201
Dr. Samantha Kumarasena: What are the components of Virchowâs triad, and can we name several etiologies within each?
Dr. Marty Fried: Pearl 3: Protein deficiencies which cause venous clotsÂ
Dr. Samantha Kumarasena: Among the classic inherited thrombophilias, what are some tests that we can use to identify protein deficiencies that could cause a hypercoagulable state? Â
Dr. Marty Fried: Pearl 4: Activating mutations which cause venous clots
Dr. Samantha Kumarasena: Which tests do we use to identify clotting factor mutations, which could lead to hypercoagulable states?
Dr. Marty Fried: Pearl 5: Learning point rewind and clinical application
Dr. Samantha Kumarasena: Stay tuned for the end where we put this all together with a few short, illustrative cases
PEARL 1: Reframing provoked and unprovoked, and some definitions
Dr. Samantha Kumarasena: Alright Marty, letâs kick things off with the venous thrombosis categories we all know and love: provoked and unprovoked. And letâs build on all the nuances from there.Â
Dr. Rebecca Karp Leaf: As a hematologist I like to put clots in two different buckets, really. So the first, the first bucket would be a provoked clot, and that means we have a clear, distinct, identifiable, and oftentimes modifiable risk factor for why you had a, uh, a clot. The second bucket is unprovoked. And that really means that, um, either we don’t know why you had the blood clot. So I say, you know, it’s idiopathic really comes out of, out of the blue, you’re walking down the street, all of a sudden you get a blood clot. And we really don’t know why. The unprovoked bucket is important because there’s nothing we can really do to minimize the risk of having a clot again, or to mitigate a risk factor. And as such that, you know, risk of having a subsequent clot,in some patients can be as high as 30% at five years. And as such he risk of a subsequent clot, likely exceeds the risk of bleeding on a blood thinner.
Dr. Marty Fried: We typically think about anticoagulating indefinitely for the unprovoked clots. The logic behind that is â while an unprovoked clot by definition doesnât have a clearly-identifiable reason for the clot, the thought is that thereâs something underlying there, that increases their risk of future clots.Â
Dr. Samantha Kumarasena: Right, and that part has always sort of made sense to me. But how often are we scratching our heads about a patient with some possible provoking factors?Â
Dr. Marty Fried: Like someone on a road trip and they get a DVT. Does that car ride really explain a big PE?
Dr. Samantha Kumarasena: So we sat down with 3 expert hematologists, and they encouraged us to actually reframe the provoked vs. unprovoked dichotomy. They suggested we think about âreversibilityâ so reversible vs. irreversible risk factors â meaning, does that risk factor reverse, or go away, with time?Â
Dr. Marty Fried: Ooooh this is a new twist on an old classic. So youâre saying it may be more helpful if we ask ourselves is this risk factor is temporary – or reversible – in the old framework we would call it âprovokedâ, and anticoagulate for just a few monthsâŠÂ
Dr. Samantha Kumarasena: On the other hand, If that risk factor sticks around â meaning itâs more difficult or impossible to reverse â we lean towards long-term treatment. Basically, the teaching point here is that an irreversible risk factor, basically puts us in the same bucket as a clot out the blue. Why is that? Because in both situations, we donât think we can fix the risk factor. So the risk of clot sticks around long-term, and so we should think about treating long-term.Â
Dr. Marty Fried: Ooh I like that. Letâs talk about how that plays out? Say you have a patient who is unfortunately immobilized by a large-territory stroke and developed a large, proximal lower extremity DVT. Sure, we can identify the provoking event.. immobility after stroke. But youâre suggesting we should ask ourselves â is that provoking factor really going away? Should we be stopping the DOAC after 3 to 6 months? In that situation of a dense infarct causing immobility Iâm not sure any of us would say a the 3 month mark âoh yeah weâre stopping anticoagulationâ . This framework sort of allows for that.Â
Dr. Samantha Kumarasena: The immobility after a devastating stroke DVT, is a good case in point. Itâs certainly a âprovokedâ clot, but itâs due to an âirreversibleâ risk factor.Â
Dr. Marty Fried: And perhaps for a more common case I think about obesity. I guess in theory itâs reversible. But in practice obesity can be an extremely d ifficult situation for patients to reverse.Â
Dr. Kenneth Bauer: I think the issue with obesity as a risk factor is unfortunately, we don’t really know what happens to your VTE risk if you lose a lot of weight? I tend to put ’em in the unprovoked category and make my decisions based on itâŠwe don’t really know what happens to your VTE risk if you lose a lot of weight? I tend to put ’em in the unprovoked category and make my decisions based on it because I don’t think it’s such an easily modifiable risk factor.Â
Dr. Marty Fried: That is Dr. Ken Bauer, a hematologist at BIDMC and professor of medicine at Harvard Medical School.Â
Dr. Samantha Kumarasena: Whether theyâve lost much weight or not, we might at least wonder about about anticoagulating patients with obesity for the longer-term. Â Â
Dr. Marty Fried: That makes sense. And who knows – boy it would be awesome if we can get DVT as another indication for GLP-1s in the future!Â
Dr. Samantha Kumarasena: Hereâs hoping! Letâs keep going with this, and think about other cases where the âprovoked/unprovokedâ distinction breaks down, and where the addition of âreversible/irreversibleâ could help us out.Â
Dr. Marty Fried: Okay, shoot.Â
Dr. Samantha Kumarasena: So really, when we talk about the paradigm breaking down, weâre talking about âprovokedâ clots that are actually âirreversibleâ.Â
Dr. Marty Fried: OK provoked, but irreversible⊠Yeah letâs reinforce that for a second. We are thinking about âreversibilityâ here as a descriptor of your provoked clot. A provoked-but-reversible clot, youâll treat for the short-term, like the post-femur facture DVT. This is the traditional situation of short term anticoagulation..Â
Dr. Samantha Kumarasena: So letâs think⊠What kind of scenarios belong in thisthat mold-breaking, provoked-but-irreversible bucket? We did talk about obesity before (since thatâs often hard to reverse), and we also talked about permanent immobility already. Some more food for thought:
(#1): Cancer â depending on how easily it can be treated. If that cancerâs progressing despite treatment, thatâs not really easily-reversed.Â
(#2) Anatomy â really, any cause of turbulent flow in a vessel, which might not actually be reversible. This could be a stent, a vascular malformation, or even the site of scarring from a prior venous clot. Youâre more likely to get a clot in that same place.Â
(#3) Inflammatory disorders â Inflammatory bowel disease is actually notorious for this. Just like we talked about with cancer, the âreversibilityâ is really dependent on whether you can get the disease under control. Also severe rheumatologic conditions like rheumatoid arthritis or lupus are some other examples which can certainly provoke a clot, and until those conditions are managed, we ought to treat them as semi-permanent conditions, and treat as such.Â
Dr. Marty Fried: Oh thatâs fascinating. So say someoneâs got bad Crohnâs, gets a DVT, and we eventually are able to get their IBD under control. Would you actually stop their DOAC?
Dr. Samantha Kumarasena: Itâs sure something to think about! Or maybe bring âem down to a little bit of prophylaxis. Weâll get into that can of worms in âHypercoagulability part 2â, so stay tuned.Â
Dr. Marty Fried: Oh Iâm not going anywhere⊠Ok, back to our provoked-irreversible bucket. You mentioned cancer, anatomic vascular situations, IBD, and some other things where we can define a provoking factor, but weâre not so sure that the typical brief course of anticoagulation is appropriate since the risk factorâs duration isnât clear. This makes up the provoked-irreversible buckedâŠÂ
Dr. Samantha Kumarasena: Quick summary of what weâve just learned: When you think about a clot, think about whether itâs âprovokedâ or âunprovokedâ for sure. And, every time you hear âprovokedâ, think about reversibility too. Is the risk factor reversible? Because thatâs really what drives our management â whether that risk factor will go away.
Dr. Marty Fried: A provoked-reversible risk factor (like peri-operative immobility) is the classic short-term treatment. A provoked-irreversible risk factor (like post-stroke immobility) is going to be treated long-term.Â
PEARL 2: Building on Virchowâs
Dr. Samantha Kumarasena: So we talked about provoked/unprovoked, and reversible/irreversible so far. The OTHER systematic way I find helpful in thinking about clots, is thinking about the underlying mechanism driving that clotâs formation. Thatâs Virchowâs triad. I think going through the exercise of using it, has made me much more thoughtful in how I think about my patients with recurrent clots..
Dr. Marty Fried: Letâs remind ourselves of what Virchowâs triad is, real quick.
Dr. Jean Connors: There are three components to developing a thrombosis. Hypercoagulability, endothelial injury or vascular damage, and stasis.
Dr. Marty Fried: Thatâs Dr. Jean Connors, our third and final expert! Dr. Connors is a hematologist at Brigham and Womenâs Hospital and the Dana Farber Cancer Institute, and professor of medicine at Harvard Medical School
Dr. Samantha Kumarasena: Letâs dive into that triad then, with a couple nuanced examples that I didnât really think about until I got to fellowship. The first of the triad of clot-drivers is stasis. Like a long plane ride, or immobilization after an injury, that fits nicely in the stasis bucket, and those are the classics. There are some surprises here, though. You might be surprised to learn that heart failure can fit under the âstasisâ category. Reduced EF means slow flow, which is a recipe for thrombosis.Â
Dr. Marty Fried: Chef HFrEF cooking up the worst in culinary clot formation.
Dr. Samantha Kumarasena: Right? itâs really any kind of sluggish or turbulent flow that predisposes to clotting. Really, any abnormality in blood flow could fit under here. So stasis is also at play with any vascular obstruction from things like tumor or pregnancy. And it also includes viscosity issues â polycythemia, leukemia, or specific monoclonal diseases like Waldenstromâs. Â
Dr. Marty Fried: Lots in the stasis bucket that I didnât think about⊠OK Iâll take the 2nd arm of the triad, endothelial dysfunction. This is sort of familiar territory. I think about atherosclerotic disease, indwelling lines, stuff like that.Â
Dr. Samantha Kumarasena: Totally! Remember that this category is more about an injury to that delicate endothelium, which exposes all that pro-clotting stuff underneath â tissue factor, von Willebrandâs, all that good stuff.Â
Dr. Marty Fried: I think you and I might have different ideas of good stuff, but please continue good Doctor
Dr. Samantha Kumarasena: Weâll have agree to disagree there Marty. So back to endothelial injury. Think about toxic or poke-y stuff that isnât supposed to be there. That includes things like bacteremia, or skin or soft tissue infections. You can think about prior toxic exposures as wellâ like radiation therapy.Â
Dr. Marty Fried: Ooo prior radiation therapy – See thatâs good stuff Sam! We know radiation to be sort of targeted tissue injury – hopefully localized to the cancer. But weâve all seen local side effects from rashes to mucositis, and we shouldnât forget that there is a vascular territory that supplies the area that could get damaged and become dysfunctional.Â
Dr. Samantha Kumarasena: And another thing â remember that old scarring from prior clots also counts as endothelial injury. Itâs the reason why if you get another clot, youâre more likely to get it in the same location as the first one.Â
Dr. Marty Fried: Clots on clots on clots. Â
Dr. Samantha Kumarasena: The last of Virchowâs triad, is hypercoagulability â inherent overactivation of the clotting system. We often think about the Factor V Leidens of the world in this bucket.Â
Dr. Marty Fried: But what most forget about is the loss of your natural anticoagulants to chronic diseases (like in cirrhosis and nephrotic syndrome). Those can also cause clots.Â
Dr. Samantha Kumarasena: So now weâve talked through two frameworks to help us think about our patients with venous clots. In Pearl 1, the reversible-irreversible idea helps us consider: just how long is that risk factor hanging around? In Pearl 2, now weâve seen how Virchowâs triad helps us think about how risk factors cause clots.Â
Dr. Marty Fried: How do we put those two ideas together, then?
Dr. Samantha Kumarasena: Letâs roll with with an example. Say weâve got a young guy, 30 years old, and he gets on a plane for 12 hours, and gets a DVT.Â
Dr. Marty Fried: Easy peasy. We heard about that one. Using Virchowâs, the airplane rideâs âstasisâ for sure, itâs a provoked clot, with a âreversibleâ risk factor, a temporary one. So youâd just anticoagulate him for the short-term.Â
Dr. Samantha Kumarasena: Now letâs make it a bit tricky. Say he was just on a plane for just 3 hours, and got that DVT. Do we think about that any differently?
Dr. Kenneth Bauer: Air travel is an interesting one. The epidemiology data is it’s strongest. The travel distance is over 3000 miles, so there’s clearly something to the distance travel, but in my view, it’s a relatively weak risk factor to be honest in let’s say a very healthy individual who develops air travel associated VT and has no other risk factors. I tend to actually put it more in the unprovoked bucket. I think it’s such a weak risk factor that I tend to regard it as more unprovoked.Â
Dr. Samantha Kumarasena:Â Just for context, he mentioned over 3,000 miles of air travel having the strongest data. That is about 5-6 hours! So over 5-6 hours of air travel is where itâs felt to be a more considerable provoked risk factor.Â
Dr. Marty Fried: Well, now Iâm kinda hard-pressed to say it was just the 3-hour plane ride. And home boy is only 30 years old. Feels like thereâs something else going on.Â
Dr. Samantha Kumarasena: Right. Youâre suspecting another risk factor (maybe an irreversible one?) might be hiding in there somewhere, since the plane ride doesnât seem enough to do it.Â
Dr. Marty Fried: Which sort of begs the question if any of t hese are hard cutoffs? For stasis – How about the guy whoâs on a plane for four and a half hours? For endothelial injury – what about the two-cigarette per day smoker? The guy who had colon cancer 5 years ago whoâs now cured? I guess Iâm just wondering how we draw hard lines in the sand about using Virchow to help us determine provoked/unprovoked, reversible and irreversible. Â
Dr. Kenneth Bauer: We don’t really have good, if you will, risk models that have been really developed. How do you draw this big divide between provoked and unprovoked and realize that it’s not dichotomous?Â
Dr. Marty Fried: Can I tell you how validating it is to hear a Harvard professor of medicine ask the same question that we have all asked on rounds – how do you draw that line between provoked and unprovoked, and perhaps there isnât a clear cutoff. It seems like one of those beautiful gray areas – which we see all the time in medicine. Itâs ok to be gray, at least thatâs what I keep telling my aging selfâŠÂ
Dr. Samantha Kumarasena: Itâs like the quote we opened this episode with – sometimes we need to get comfortable with being a little uncomfortable – thatâs ok! So to summarize this pearl âwhen you have a new DVT or PE, think through Virchowâs triad. Is it stasis? In that bucket goes immobility, or any sluggish flow with heart failure, vascular obstruction and hyperviscosity syndromes.
Dr. Marty Fried: Is there an endothelial injury at play from bacteremia, soft tissue infections or prior radiation?Â
Dr. Samantha Kumarasena: Is it hypercoagulability with inherited thrombophilias that we will talk about in a second, or is it the loss of natural anticoagulants to chronic disease, like cirrhosis or nephrotic syndrome?Â
Dr. Marty Fried: And we learned a quick tidbit in our application exercise that stasis with air travel becomes more at play after 5 or so hours. But even then, itâs a bit weaker of a risk factor, so keep your eyes peeled for other risk factors at play.
Dr. Samantha Kumarasena: Weâll link a handy infographic in our show notes and socials. This graphic puts Virchowâs triad together with our reversibility concept. Hopefully itâll help you elevate your differential for these clots!
Dr. Marty Fried: So letâs turn our attention to those TRULY unprovoked clots. Like weâve gone through Virchowâs and still drawing blanks. Is that when I start thinking about Factor V Leiden?Â
Dr. Samantha Kumarasena: Ya know what, letâs talk about it. Itâs complicated.Â
PEARL 3: Unprovoked clots and hypercoagulability testing, Part 1: protein deficiencies
Dr. Marty Fried: Letâs go back to our guy who sat on a plane for 3 hours and got a DVT. What do we do for him? We probably should be thinking about some underlying disorder, one of those heritable conditions? Sounds like maybe this is a situation we would throw around some hypercoag tests?
Dr. Jean Connors: You have to know what you want to do with the results and how to use the results for thrombophilia testing before you actually order the tests.
Dr. Samantha Kumarasena:So lets get more thoughtful about these tests. When we talk about the classic thrombophilia testing, for the purposes of this episode, weâre really talking about testing for the inherited thrombophilias. Now there are also acquired thrombophilias. The big scary one in that group is antiphospholipid antibody syndrome, or APLAS, but that there is a whole separate beast. Weâll get to that in the next episode.Â
Dr. Marty Fried: Iâve certainly seen patients with APLAS, and that situation is no joke .
Dr. Samantha Kumarasena: Yeah it really isnât.The inherited guys are friendlier, so letâs stick with them first.
Dr. Marty Fried: Alright Iâm down to make some friendsâŠ
Sam: Great! Letâs start with some introductions! There are two groups of inherited thrombophilias: protein-deficiencies, and overactive-factors. In the first group are the three protein-deficiencies, which are deficiencies in the bodyâs natural anticoagulants. The second group features the two overactive-factors, which are clotting factors that donât turn off. So five tests in total – thatâs it! In this pearl, weâre going to focus on that first group, the three protein-deficiencies! Â
Dr. Marty Fried: Love it, so remind me what are those conditions again?Â
Dr. Samantha Kumarasena: The 3 classic inherited protein deficiencies that can cause clots are: Antithrombin III deficiency, Protein C deficiency, and Protein S deficiency.Â
Dr. Marty Fried: Oh boy. Do I really have to remember what these guys do again?Â
Dr. Samantha Kumarasena: Come on, weâre making friends! They might have drifted away since you first met them, but weâre open to reconnecting? Maybe Maybe weâll start with what these proteins do for a living, to help us understand how they cause problems when theyâre deficient.
Dr. Marty Fried: Iâm trusting you here SamâŠ
Dr. Samantha Kumarasena:  Youâll be fine Marty – Our first friend is Antithrombin III. Remember that she works alongside heparin in preventing clots â and we know heparin. We love heparin. Heparin, and her low molecular weight cousins, all work by increasing the activity of antithrombin III.
Dr. Marty Fried: Well doncha knowâŠ. So more antithrombin III, less clotting⊠less antithrombin III, more clotting.
Dr. Samantha Kumarasena: Exactly – and fun fact: say you have a patient whoâs on a heparin drip, and theyâre just not getting therapeutic despite massive horse-doses of heparin. ATIII deficiency is one item on your differential in that situation.Â
Dr. Marty Fried: Alright antithrombin III – I feel like I already know you⊠Well, pleasure to meet you, again,. I think Iâm going to like youâŠÂ
Dr. Samantha Kumarasena: Our next two friends round out this section – they are Protein C and S. Theyâre besties! They go everywhere together. And how do they work? These two inhibit factors V and VIII.Â
Dr. Marty Fried: Ruh roh Sam Iâm getting dangerously close to a clotting cascade-induced vagal episode.
Dr. Samantha Kumarasena: Hang in there Marty, this one isnât that bad. Think about it this way. Factors V and VIII make clot. And what do protein C and S do? They inhibit factor V and VIII, making less clot. So more protein C and S, means less factor V and VIII, and less clotting. With protein C and S deficiency, factor V and VIII are uninhibited, and so we get more clots.
Dr. Marty Fried: Think about protein C and S as key clot defenders.. And a deficiency is benching those players. Without protein C or protein S, our team is liable to give up some easy DVTs… Iâm a Browns fan I know a lot about crappy defense.Â
Dr. Samantha Kumarasena: Another pathophys fun fact: when you start warfarin, you actually briefly create a Protein C and S deficiency. That deficiency causes two things: (#1) low protein C and S is the reason why the first few days of warfarin are associated with a paradoxically increased clotting risk. (#2) the protein C and S deficiency is actually the driver behind warfarin skin necrosis. Both of these high-clot situations are the direct result of warfarin creating a protein C and S deficiency for us.Â
Dr. Marty Fried: Ok. These fellows also seem like decent folk. I guess that could have been worse. Possibly. Still a little pre-syncopal
Dr. Samantha Kumarasena: Thatâs the spirit! Now⊠the thing is this isnât binary! For all these deficiencies â antithrombin III, protein C, protein S âitâs not just about if itâs gone, but also how much functional protein is gone. We can test for the protein itself with an antigen test as well as its activity level. The activity level is basically a percentage of how much normal functioning youâve got.Â
Dr. Marty Fried: My spidey senses are tingling. I feel like thereâs a catch hereâŠÂ
Dr. Samantha Kumarasena: Yeah⊠The reason weâre not sending these tests all the time, is because interpreting the results can be a real headache. These tests are subject to a TON of interference. Â
Dr. Marty Fried: There is actually five big ones we want listeners to remember that can make your patient look like they have protein C, S and antithrombin deficiency. Ok First up..
Dr. Jean Connors: Any dose of anticoagulant will also affect these assays. So protein C, protein S and antithrombin can be affected by the presence of any type of anticoagulant, whether it be a direct oral anticoagulant, heparin, bivalirudin. So it doesn’t really benefit to test at that time.
Dr. Marty Fried: Bummer. So the anticoagulant we just started is going to mess up all our tests, itâs going to make the patient look like they have a deficiency when they really donât. Fine then. Wait⊠so just test before you start anticoagulation, right? Problem solved!
Dr. Kenneth Bauer: So antithrombin is problematic in a way that if you get a low level even before you start any heparin, it could be affected by a very large clot burden.
Dr. Samantha Kumarasena: Thatâs because these factors â whether antithrombin III, protein C, or protein S â can get consumed by trying to break down such a large clot.Â
Dr. Marty Fried: So the 2nd big situation that can make it look like your patient has an inherited deficiency when they do not is a large clot.Â
Dr. Samantha Kumarasena:Â Yep –Â even before you start anticoagulation, you can also get fooled into thinking thereâs a deficiency, when there isnât – simply related to the patient’s clot burden.Â
Dr. Marty Fried: And if you think about it – those are the situations when you are inclined to test patients – these big scary clots in young healthy people weâre thinking something must be wrong here!Â
Dr. Samantha Kumarasena: And thatâs a real deficiency, you know? Your patient would actually have low levels of those factors because they have a big clot. But itâs not an inherited deficiency. The low level is just temporary, due to the size of the clot.Â
Dr. Marty Fried:Â Yeesh. Can it get any worse?
Dr. Samantha Kumarasena: Itâs not just blood thinners and clot burden that mess up our tests. The 3rd big reason why we should interpret these tests with caution, is that you can get a false low level for the very reason your patientâs in the hospital —- often inflammation to some degree or another.Â
Dr. Jean Connors: When you’re inflamed, here is less free protein S available to participate in its anticoagulant effects as a co-factor with protein C. So you actually kind of develop a hypercoagulable state and that is not persistent when the inflammation leaves, you should not label your patient as being protein S deficient.Â
Dr. Marty Fried: Lots of reasons to be inflamed, certainly need to be aware of that situation mucking up our tests
Dr. Samantha Kumarasena: Yes and now onto the last two conditions and these are more specific for causing low protein C and S. First up if you see a low protein C and S, ask yourself is liver disease playing a factor?
Dr. Marty Fried: Yeah thats a good point! Protein C and S are also vitamin-K dependent. So when the liver goes, vitamin-K dependent factors go too. That doesnât mean theyâve got an inherited deficiency â they just have another genuine reason to have low levels.
Dr. Samantha Kumarasena: Yes and then the last big one is estrogen!
Dr. Jean Connors: Protein C protein S altered by estrogen state, right? So a lot of times I’ll see women who’ve had a pregnancy loss and someone says, oh, is the pregnancy loss due to antiphospholipid syndrome? And they send these tests and they send inherited thrombophilia tests as well. And you’ll find low protein C protein S, because that’s what estrogen does. Estrogen creates a hypercoagulable state by driving up the procoagulant proteins. So fibrinogen goes up, factor VII goes up, and protein C in protein S go down. So the acute setting may not be the time to test for activity levels.Â
Dr. Samantha Kumarasena: Itâs pretty crazy how estrogen causes clots by creating protein C and S deficient state, even messing up fibrinogen, favor 7 and more. so weâre talking lots of ways estrogen can cause havoc..
Dr. Marty Fried: I have three daughters Sam, I am well aware of the havoc that estrogen can cause⊠but the bottom line, it sounds like if someoneâs on an estrogen-containing OCP and has a clot, itâs going to be really tough to interpret protein C and protein S levels.
Dr. Samantha Kumarasena: Interesting tidbit – the hypercoagulability in high estrogen states is actually an evolutionary adaptation to protect against bleeding during childbirthâŠÂ
Dr. Marty Fried: Darwin FTW?Â
Dr. Samantha Kumarasena: Finch beaks and estrogen⊠who would have thought. Letâs do a quick recap, Protein C, S and antithrombin can be falsely low in the setting of 1) ANY anticoagulation, 2) large clot burden, 3) acute inflammation. And then liver disease affects only protein C and S because they are vitamin-K dependent factors, but itâs still a big asterisk there. As well as high estrogen states.
Dr. Marty Fried: Sheesh. Lots of reasons for falsely abnormal⊠But could I at least reassure myself if we get a normal result back ?
Dr. Samantha Kumarasena: Thatâs the thing â normal tests arenât really reassuring. Especially with DOACs and antithrombin III. In the test tube, the DOAC will falsely act like antithrombin III. So if this guy had a real antithrombin III deficiency, but heâs already started a DOAC, the test might think the DOAC is antithrombin III and it will be falsely normal. Now antithrombin III is the classic example. But itâs true for the other tests tube.Â
Dr. Marty Fried: Ugh DOAC being a decoy!!
Dr. Samantha Kumarasena: So basically â it is kind of frustrating — no matter what the level is, the test could be wrong. And you wonât necessarily know if itâs a real deficiency, test artifact, or their physiology at the time.Â
Dr. Marty Fried: Another way to look at it is thereâs a whole differential diagnosis for an apparent deficiency of one of these protein tests. Imagine youâve got a deficiency of, letâs say⊠ATIII. Whatâs on your differential?
- A true, inherited deficiency thatâs the cause of their clot.Â
- A deficiency thatâs definitely there, but isnât actually inherited.Protein C and S and antithrombin III might be caused by some underlying disease (like cirrhosis or nephrotic syndrome), or acute inflammation, high-estrogen state, or maybe by a really big clot eating up all the factors. This is like a temporary deficiency, but itâs not the cause of their clot.Â
- A fake-deficiency. Something thatâs an artifact of how the test works in the test tube. As in, say youâre testing a patient on a heparin drip. It could look like your ATIII level is low, even when it isnât.Â
Dr. Samantha Kumarasena: Exactly Marty – our big picture message is generally to avoid sending these protein tests in the acute setting. Now, of course like everything else in medicine, this isnât black-and-white. There are situations where we as hematologists DO send these tests in the acute setting. But it gets REALLY nuanced and hairy real fast. In general, if youâre wondering whether this testing is relevant in a scary clot situation, ask a hematologist for help.Â
PEARL 4: Unprovoked clots and hypercoagulability testing, Part 2: overactive factors
Dr. Samantha Kumarasena: So⊠Letâs talk about the last two thrombophilia tests. These last two are the gene guys: Factor V Leiden, and the prothrombin G20210A. Theyâre both genetic tests, for specific genetic variants that cause overactive factors. What does an overactive factor mean? Factor V Leiden and the prothrombin gene mutation lead to clotting factors becoming active due to the presence of a mutation. This is different from the other tests that we talked about before, which are generally quantitative deficiencies â where you just donât have enough protein C or S.Â
Dr. Marty Fried: If I had to guess, Factor V Leidenâs got to be hyperactive Factor V, and prothrombin G-yadda yadda yadda got to be hyperactive prothrombin?Â
Dr. Samantha Kumarasena: Spot on!Â
Dr. Marty Fried: Well, that wasnât too bad.Â
Dr. Ken Bauer: If you do the genetic tests (Leiden or thrombin), those can be done anytime because they’re genetic on the patient’s DNA. So those are no problem to do, assuming that they haven’t been given blood transfusions or things that might have leukocytes in them or contaminating DNA, but those could be done anytime.Â
Dr. Samantha Kumarasena: Â At least these Factor V Leiden and Prothrombin genetic tests are kind of trustworthy.
Marty: Love it when interpretation is simple, unless there is a schick with these tests as wellâŠ.Â
Dr. Jean Connors: I like to point out to people that currently something like 39% of the US population is considered obese and the risk, the odds ratio for getting a DVT due to obesity is about the same as for heterozygous prothrombin gene mutation. So when we’re looking for what’s common, obesity is a lot more common than a heterozygous prothrombin gene mutation.Â
Dr. Marty Fried: Naturally itâs not quite so simple⊠It sounds like the issue here isnât necessarily is the test results are accurate or not, itâs whether or not the presence of the mutation is really what caused the clot?Â
Dr. Jean Connors: The Factor V Leiden alone, is often not enough. So there are some families that have Factor V line mutation through multiple generations and no one has ever had a clot. And then there are some families that have factor five line mutation and many family members have had clots in their twenties, thirties, fortiesâŠ
Dr. Samantha Kumarasena: The teaching point here is that factor V Leiden has variable penetrance, so it affects everyone differently. Some families have it, but have no clots at all.Â
Dr. Marty Fried: And Iâm guessing it matters whether or not someone has one or two wonky alleles.Â
Dr. Jean Conners: Some of these people are homozygous. And that certainly makes it even easier for you to get a clot if you’re homozygous compared to heterozygous. But we think that there are other either genetic modifiers or environmental factors that make factor five leiden behave differently from family to family. We have not been able to identify what those are. Yes a homozygous factor 5 leiden changes risk of clot, but its rare. The causative link isnât necessarily 1:1.Â
Dr. Marty Fried: Fair – so what about people with a strong family history? Are those the people you test, the ones whoâve proven to somewhat clot-prone?
Dr. Kenneth Bauer: The paradox in all this is just having a family history without having thrombophilia carries a risk in family members, and I think that’s under appreciated. So there are studies that just having family history of VTE E, so just that dad, even if he didn’t have lighted their kids, would probably have had a twofold increase of VTE. So that’s another reason why the controversy about thrombophilia testing stands because even if you test negative, it still probably the family history still should be taken account in terms of maybe how you might counsel somebody about this issue.Â
Dr. Marty Fried: Then itâs really the family history we should care about instead.
Dr. Rebecca Karp-Leaf: I would say that the, the most important thing really is, you know, sort of biology trumps any lab tests. So if, you know, you have a family where, you know, you have multiple generations of patients who are getting clots and you do all the testing and it’s negative, that doesn’t obviate the fact that they’re all having clots.Â
Dr. Marty Fried:Â How do I think about family history? Age is also a huge provoking factor too â so what do I make of clots in older family members?
Dr. Jean Connors: Certainly patients over the age of 60 who develop a DVT, they’re allowed regardless of thrombophilia status.Â
Dr. Marty Fried: So weâre kind of allowed a free DVT when we hit 60? Good to know.
Dr. Samantha Kumarasena: Gee, now Iâve got something to look forward to! So yes, the caveat to family history is that age itself is a provoking factor too (albeit an irreversible one). As we get older, our endothelium gets more disrupted and more prothrombotic. So a first clot at the age of 60 doesnât exactly scream âinherited clotting disorderâ. An inherited disorder usually presents earlier.Â
Dr. Marty Fried: Weâll say it again â when we say âfamily historyâ weâre talking about more than just a DVT in Grandma! Weâre talking about a persistent, concerning trend in relatives under 60.
Dr. Samantha Kumarasena: So itâs not about the tests really, itâs how the clots actually manifest in the patient and their family. The result of the test sorta⊠matters less?
Dr. Jean Connors: People test to maybe explain why someone had a thrombosis, but it should not be used to guide duration of treatment. In other words, if you had your appendix out and you developed a DVT and someone tested you and you happen to have Factor V Leiden, that does not mean that you need lifelong anticoagulation, right? You had a clearly surgically provoked and likely inflammation provoked as well thrombotic event that does not need more than three to six months of anticoagulation.Â
Dr. Marty Fried: I see. So all these arent going to change much in terms of management. Iâm still not sure why I am allowed to order themâŠ
Dr. Samantha Kumarasena: But of course, the devilâs in the details, and there are exceptions out there.
Dr. Jean Connors: The only time I think it is helpful is for women of childbearing age who might use estrogen progesterone combination, oral contraceptive pills and possibly during pregnancy.
Dr. Kenneth Bauer: So that’s a decision then that you will have to face whether if you test positive whether your children should be tested. I will oftentimes ask that question even before testing and the concern will become if they have daughters because they then might be affected. Let’s say if dad had Factor V Leiden, to go start checking his daughters, what I do tell him is the issue of course is going to be based largely around oral contraceptive use.
Dr. Marty Fried: Wow. So itâs sounding like one caveat to our âdonât testâ vibe is that if your patient is planning a high-estrogen state and there appears to be a strong family history – this is when they might let me order these fancy testsâŠÂ
Dr. Samantha Kumarasena: Yep and a high estrogen state includes pregnancy! Or estrogen-containing gender-affirming care. Â
Dr. Marty Fried: And the implication there is that this might actually change your management, as Dr. Connors said. We might change your contraceptive to a progesterone-only formulation, or perhaps even consider DVT prophylaxis during pregnancy.Â
Dr. Samantha Kumarasena: Right – because testing the parents here may not change much about their anticoagulation course as much as as it helps us help their children. Itâs honestly a super gray area though â and probably depends on the hematologist.Â
Dr. Marty Fried: As I have found with most things in life Sam, itâs really just all about my daughters. (insert another dad joke about world revolves around daughtersâŠ.)
Dr. Samantha Kumarasena:There can be some patient-centered reasons to send testing, at the appropriate time.Â
Dr. Rebecca Karp-Leaf: I think, the psychology of the clotting of thrombosis is also important. So I have probably a lower threshold to test, you know, maybe than, than other, than other people because, I do think it helps patients sometimes understand the biology of, of, you know, of their condition and they understand maybe why we’re more apt to, to continue longer term anticoagulation.
Dr. Samantha Kumarasena: Yeah, to be honest even in my hematology clinic, the discussions we have about testing can sometimes get controversial. These tests, they arenât the friends weâre texting on the daily. But we can reach out to them in a pinch.Â
Dr. Marty Fried: Letâs quickly summarize. The gene-based tests (factor V and prothrombin) arenât affected by any of the state we talked about in pearl 3 so thats win, but theyâre still vulnerable to the big drawbacks of thrombophilia testing. Remember, if you meet a patient with a factor V leiden or prothrombin mutation in their one-liner, it doesnât necessarily mean theyâre definitely going to get clots. Also remember that family history trumps. Thatâs the core message of this pearl.
Dr. Samantha Kumarasena: So when could you actually think about sending all the thrombophila tests (so thats the 3 protein factors ones ⊠and the genetic test oneâŠ.)?
Number 1: The standard scenario we think about is a patient with lots of clots at a young age with no good reason for them, and a strong family history.Â
Number 2: Consider in a patient with the right family history, you could test your patient to help counsel their children, especially daughters considering OCPs and pregnancy. Youâre probably referring to a hematologist for this one.Â
Number 3: In a patient where knowing why is really important to them, you can have a conversation about testing. But keep in mind that a negative test isnât necessarily reassuring â it doesnât negate the fact that theyâve had a clot.Â
PEARL 5: REWIND AND APPLICATIONS
Dr. Marty Fried: Ok Sam – Weâve covered a lot of ground in this episode. Letâs put the key points together one more time
Dr. Samantha Kumarasena: You got it. Build on your framework of provoked vs unprovoked with the idea of reversibility – super important in those minimally provoked situations
Dr. Marty Fried: There are 5 inherited thrombophilia tests total: three protein-deficiencies, and two overactive-proteins. The three protein-deficiencies are antithrombin III, protein C, and protein S.Â
Dr. Samantha Kumarasena: You can get falsely-low protein levels in a patient whoâs already on anticoagulation (most anticoagulants interfere with all three). You can also get TRULY low levels in a patient with a huge clot burden. A low level doesnât always mean they inherited a deficiency. For Protein C and S specifically, you can get TRULY low levels in liver disease and high-estrogen states. Doesnât mean your patient inherited a deficiency either.Â
Dr. Marty Fried: The gene-based tests (factor V and prothrombin) can be sent off at anytime – but our big picture message is should you? A patient with a heterozygous factor V leiden or prothrombin mutation in their one-liner does NOT necessarily mean theyâre definitely going to get clots. And family history is more important than presence or absence of the gene-based testsÂ
Dr. Samantha Kumarasena: So with that, letâs apply all this newfound clot-tastical knowledge. I have a few quick cases for you Marty.
Dr. Marty Fried: Ready!
Dr. Samantha Kumarasena: Letâs say youâve got a 48 year old guy, totally healthy, who twists his ankle and spends a day or two on the couch. A week later, he has a DVT and a subsegmental PE.Â
Dr. Marty Fried: Iâm interested in the netflix he got accomplished, but please continue.Â
Dr. Samantha Kumarasena: You find out that his mother had a PE at age 50, totally unprovoked, and his sister also had a PE two weeks postpartum, at age 25. Heâs admitted to your inpatient service, and at this point heâs already on a heparin drip. What should we suspect? Should we send any tests, and which ones?
Dr. Marty Fried: Oooh – this sounds like a bit more than a simple apix-and-chill situation⊠Pause here for a minute to think through how youâll manage this binge-watching bro. Okay, this guy is technically provoked, and reversible since that provoking factor is going away. But itâs a pretty weak provoking factor. Who among us hasnât crushed Breaking Bad in 2 days without catching a PE? And we got this family history, Iâm definitely thinking of something heritable. But heâs on heparin, so Iâm mostly limited to sending the gene tests for now, arenât IâŠ? Since the overactive factors protein C, S and antithrombin are affected by heparin. So at this point Iâm thinking about sending Factor V Leiden and prothrombin G-yadda yadda. Probably make sure heâs up to date on his cancer screenings. And yeah, leaning toward throwing him on a DOAC, and outpatient Heme follow-up for the rest.Â
Dr. Samantha Kumarasena: I like it! We donât expect these tests to change our immediate management inpatient. Fair to turf. Outpatient Heme follow-up is an important bit here. Certainly if heâs got something pop up, heâd be a candidate for long-term AC. If itâs all negative, it could go either way, short-term or long-term. Definitely worth a discussion with Hematology and the patient in terms of their risk tolerance for re-thrombosis. A teaser for Episode 2 here: the ONE exception is if youâre suspecting anti phospholipid syndrome, or APLS. Weâll get to APLS in the next episode â itâs a whole beast in itself.Â
Dr. Marty Fried: Thatâs fair. And a good reminder not to forget about APLS, even when thinking about venous clots. Itâs a do-not-miss for sure.
Dr. Samantha Kumarasena: Letâs think about a different situation. Youâre in the clinic talking to a 40 year-old mom who just got a DVT/PE combo after twisting her ankle. Itâs a first-time clot. And maybe thereâs a less family history: say a recent DVT in a 70-year-old aunt, but nothing else. She just finished 3 months of a DOAC. But she also has a 16 year-old daughter whoâs thinking about an OCP.Â
Dr. Marty Fried: Ahh the teenage daughters throwing some complication as per usual⊠Pause here if youâd like some time to think about it! Geez. So Iâm still considering her clot after twisting her ankle and likely not moving much in the provoked-reversible paradigm. Itâs still a weak factor, I know that. Her family history isnât very strong â at 70 years old, that auntâs risk factor was most likely her age itself. I donât think Iâd test just based on that. But my gut feeling is, Iâd at least want to talk to them about testing because of her daughter. If our patient has a mutation or something possible heritable, weâd want to avoid an OCP for the daughter. Maybe Iâd have them talk to a hematologist about it.Â
Dr. Samantha Kumarasena: And fortunately, she already finished 3 months of that DOAC!Â
Dr. Marty Fried: Right! So weâre not limited in the tests we can send! Maybe weâd send them all – the gene tests and the protein tests: protein C, S, and ATIII and FVL and prothrombin. Iâm going to sound so sophisticated the next time I consult heme for a blood clot. Iâm so excited.Â
Dr. Samantha Kumarasena: Youâll blow them away!
Dr. Marty Fried: All right folks, thatâs the end of Episode 1. Thanks so much for listening! Tune in next episode to talk about management. Letâs keep building on that reversibility idea. Beyond just testing â how does this translate into anticoagulation decisions? And how does APLS fit in with all this?Â
Penelope, Ophilia and Madeline: If you found this episode helpful, please share with your team and colleagues and give it a rating on Apple podcasts or whatever podcast app you use! It really does help people find us!Â
Thanks to our reviewers for this podcast. Thank you to Jerome Reyes for the audio editing and Steven Parkin for the accompanying graphics.Â
Opinions expressed are our Daddy’s and his friends alone and do not represent the opinions of any affiliated institutions. Thank you!
References
- Reference in AMA format. PMID
- Reference in AMA format. PMID
- Reference in AMA format. PMID
- Reference in AMA format. PMID
- Reference in AMA format. PMID
Tags: clot formation, hematology, hypercoagulability, thrombophilia
2 comments on “Hypercoagulability Workup: Five Pearls Segment”
Hi, I’m unable to access the citation for “no difference between 3 or 6 months of AC”
Sorry about that Arsh! Will loop in the right people to change/email you.